Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSPI 0056901 approvals13 trials

Pharmicell Co.,Ltd.

Official website

Pharmicell, founded in 1968 and listed in 1988, operates biomedical and biochemical divisions in stem cell therapeutics and fine chemicals.

As of 2026-10-10, Pharmicell Co.,Ltd. has 1 Korean MFDS drug approval, 33 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Pharmicell was founded in 1968 and listed on the KOSPI in 1988 as a biopharmaceutical company operating a Biomedical division and a Biochemical division. The Biomedical division develops the stem cell therapy Hearticellgram-AMI, runs an adult stem cell storage business, and produces cosmetics containing stem cell culture extract, while the Biochemical division, built around 아이디비켐(주) which was acquired in 2012 and merged in 2013, manufactures electronic materials, pharmaceutical intermediates such as Nucleoside and mPEG, and eco-friendly phosphorus-based flame retardants. For the 58th fiscal term, revenue totaled 114,062, with 111,538 from the Biochemical division and 2,524 from the Biomedical division.

Products & technology

  • Hearticellgram-AMIStem cell therapy
  • Adult stem cell storage serviceAdult stem cell storage
  • Cosmetics containing stem cell culture extractCosmetics
  • Electronic materialsElectronic materials with low dielectric constant and loss
  • Pharmaceutical intermediates (Nucleoside, mPEG)Pharmaceutical intermediates
  • Phosphorus-based flame retardantEco-friendly phosphorus flame retardant for textile and electronic materials

Regulatory approvals

data.go.kr

1 Korean MFDS drug approvals · 2021

  • MFDS drugHearticellgram-AMI2021-08-26
    Drug · Prescription · Approval202106185

Clinical trials

data.go.kr

13 MFDS clinical trial authorisations · 2012–2024 (Phase 1 6 · Phase 2 4 · Phase 3 2 · Phase 4 1)

  • Phase 2셀그램이디(Cellgram-ED)2024-08-02

    4 trial sites

  • Phase 1셀그램-씨케이디 (Cellgram-CKD)2021-07-27

    1 trial site

  • Phase 3셀그램-엘씨 (Cellgram-LC)2020-12-02

    15 trial sites

  • Phase 1셀그램-디씨-피씨 (Cellgram-DC-PC)2020-06-25

    1 trial site

  • Phase 1셀그램-디씨 (Cellgram-DC)2020-06-25

    1 trial site

  • Phase 2셀그램이디(Cellgram-ED)2020-06-11

    4 trial sites

  • Phase 1셀그램이디(Cellgram-ED)2019-01-14

    1 trial site

  • Phase 2셀그램-엘씨 (Cellgram-LC)2015-12-16

    10 trial sites

  • Phase 1셀그램이디(Cellgram-ED)2014-09-26

    1 trial site

  • Phase 1Cellgram-CLI2014-09-22

    1 trial site

  • Phase 2셀그램-엘씨 (Cellgram-LC)2012-11-06

    12 trial sites

  • Phase 3MSC2(하티셀그램-에이엠아이)2012-07-09

    5 trial sites

Show 1 more
  • Phase 4MSC2(하티셀그램-에이엠아이)2012-03-23

    4 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 8 more trials

Key disclosures

KRX KIND via OpenDART
Show 5 more events

Publications

PubMed · affiliation-matched
Show 23 more publications

Patents

KIPRIS · applicant-matched
Show 25 more patents

AI reads

MAA server logs · IP-verified
70
Times AI engines pulled Pharmicell Co.,Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

2
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

68
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

12
live 0
Last 7 days
55
live 2
Last 30 days
70
live 2
All time
  • OpenAIChatGPT-Userlive2
  • OpenAIOAI-SearchBot61
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2
  • MicrosoftBingbot1
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Pharmicell Co.,Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · R&D. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition